Role of humoral immunity in host defense against HIV

Current HIV/AIDS Reports

Volumn 7, Issue 1, 2010, Pages 11-18

  Baum, Linda L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ADCC; ADCVI; Antibodies; Broadly neutralizing antibodies; Catalytic antibodies; HIV; Neutralizing antibodies

Indexed keywords

BROADLY NEUTRALIZING ANTIBODY; CATALYTIC ANTIBODY; CROSS REACTING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELL MEDIATED VIRAL INHIBITION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; CELLULAR IMMUNITY; CROSS REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; INFECTION PREVENTION; INFECTION SENSITIVITY; NATURAL KILLER CELL; NONHUMAN; PROTEIN CONFORMATION; REVIEW; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LOAD;

AIDS VACCINES; ANIMALS; ANTIBODIES, CATALYTIC; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CROSS REACTIONS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, HUMORAL; VIRAL LOAD;

EID: 77249085588     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-009-0036-6     Document Type: Review

References (50)

1. RP Sekaly 2008 The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205 7 12 10.1084/jem.20072681 18195078 (Pubitemid 351185709)
2. SP Rerks-Ngarm S Pitisuttithum J Nitayaphan, et al. 2009 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand N Engl J Med 361 2209 2220 10.1056/NEJMoa0908492 19843557 This large HIV vaccine trial in Thailand had modest protection (30%) against HIV infection.
3. T Demberg RH Florese MJ Heath, et al. 2007 A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques J Virol 81 3414 3427 10.1128/JVI.02453-06 17229693 (Pubitemid 46456650)
4. Y Li K Svehla MK Louder, et al. 2009 Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals J Virol 83 1045 1059 10.1128/JVI.01992-08 19004942 This analysis looked at polyclonal sera from individuals with broadly diverse HIV gp120-specific neutralizing antibodies and found that not all of this reactivity was against the CD4 binding region.
5. S Zolla-Pazner P Zhong K Revesz, et al. 2004 The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1 AIDS Res Hum Retroviruses 20 1254 1258 10.1089/aid.2004.20.1254 15588347 (Pubitemid 39557875)
6. DN Sather J Armann LK Ching, et al. 2009 Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection J Virol 83 757 769 10.1128/JVI.02036-08 18987148 The longer an individual is infected with HIV and the higher the plasma viral load, the more heterologous neutralizing antibodies he or she will have.
7. MJ van Gils Z Euler B Schweighardt, et al. 2009 Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression AIDS 23 2405 2414 10.1097/QAD.0b013e32833243e7 19770692
8. NA Doria-Rose RM Klein MM Manion, et al. 2009 Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies J Virol 83 188 199 10.1128/JVI.01583-08 18922865 Aviremic long-term nonprogressors were less likely to have antibodies that neutralize diverse strains of HIV. The authors also found a higher percentage of peripheral HIV env-specific B cells than expected in HIV-infected individuals.
9. JM Binley EA Lybarger ET Crooks, et al. 2008 Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C J Virol 82 11651 11668 10.1128/JVI.01762-08 18815292
10. MD Simek W Rida FH Priddy, et al. 2009 Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm J Virol 83 7337 7348 10.1128/JVI.00110-09 19439467 This study identified a cohort of elite neutralizers, not to be confused with ECs. These individuals are special because they make "broad and potent" neutralizing antibodies against HIV.
11. I Bontjer A Land D Eggink, et al. 2009 Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution J Virol 83 368 383 10.1128/JVI.01404-08 18922866
12. J Liu Y Deng AK Dey, et al. 2009 Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation Biochemistry 48 2915 2923 10.1021/bi802303b 19226163
13. LM Walker SK Phogat PY Chan-Hui, et al. 2009 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Science 326 285 289 10.1126/science.1178746 19729618
14. KL Davis F Bibollet-Ruche H Li, et al. 2009 Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1V3-specific antibodies in human plasma J Virol 83 1240 1259 10.1128/JVI.01743-08 19019969
15. B Dey K Svehla L Xu, et al. 2009 Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site PLoS Pathog 5 e1000445 10.1371/journal.ppat.1000445 19478876
16. SG Deeks B Schweighardt T Wrin, et al. 2006 Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses J Virol 80 6155 6164 10.1128/JVI.00093-06 16731954 (Pubitemid 43849193)
17. FS Pereyra T Palmer BL Miura, et al. 2009 Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters J Infect Dis 200 984 990 10.1086/605446 19656066
18. O Lambotte G Ferrari C Moog, et al. 2009 Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers AIDS 23 897 906 10.1097/QAD.0b013e328329f97d 19414990 These investigators studied a French cohort of ECs and showed that they did not have more neutralizing antibodies than progressors, but they did have more antibodies that mediate ADCC.
19. M Mahalanabis P Jayaraman T Miura, et al. 2009 Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers J Virol 83 662 672 10.1128/JVI.01328-08 18987151
20. MK Gorny JP Moore AJ Conley, et al. 1994 Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 J Virol 68 8312 8320 7525987
21. A Trkola M Purtscher T Muster, et al. 1996 Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 J Virol 70 1100 1108 8551569
22. DR Burton J Pyati R Koduri, et al. 1994 Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody Science 266 1024 1027 10.1126/science.7973652 7973652
23. T Muster F Steindl M Purtscher, et al. 1993 A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 J Virol 67 6642 6647 7692082
24. MB Zwick AF Labrijn M Wang, et al. 2001 Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41 J Virol 75 10892 10905 10.1128/JVI.75.22.10892- 10905.2001 11602729 (Pubitemid 33034579)
25. JM Binley T Wrin B Korber, et al. 2004 Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies J Virol 78 13232 13252 10.1128/JVI.78.23.13232-13252.2004 15542675 (Pubitemid 39507829)
26. JR Mascola G Stiegler TC VanCott, et al. 2000 Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies Nat Med 6 207 210 10.1038/72318 10655111 (Pubitemid 30082367)
27. JR Mascola MG Lewis G Stiegler, et al. 1999 Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies J Virol 73 4009 4018 10196297
28. V Martinez MC Diemert M Braibant, et al. 2009 Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation Clin Infect Dis 48 123 132 10.1086/595013 19035778
29. ES Gray N Taylor D Wycuff, et al. 2009 Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors J Virol 83 8925 8937 10.1128/JVI.00758-09 19553335
30. EM Bunnik MJ van Gils MS Lobbrecht, et al. 2009 Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection Virology 390 348 355 10.1016/j.virol.2009.05.028 19539340
31. S Bryson JP Julien RC Hynes EF Pai 2009 Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications J Virol 83 11862 11875 10.1128/JVI.01604-09 19740978
32. SM Dennison SM Stewart KC Stempel, et al. 2009 Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions J Virol 83 10211 10223 10.1128/JVI.00571-09 19640992
33. RJ Pejchal S Gach FM Brunel, et al. 2009 A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies J Virol 83 8451 8462 10.1128/JVI.00685-09 19515770
34. DN Forthal G Landucci TB Phan J Becerra 2005 Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1 J Virol 79 2042 2049 10.1128/JVI.79.4.2042- 2049.2005 15681406 (Pubitemid 40204561)
35. AW Chung E Rollman RJ Center, et al. 2009 Rapid degranulation of NK cells following activation by HIV-specific antibodies J Immunol 182 1202 1210 10.4049/jimmunol.0713637 19124764
36. Q Liu Y Sun S Rihn, et al. 2009 Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection J Virol 83 8705 8712 10.1128/JVI.02666-08 19553339
37. LL Baum KJ Cassutt K Knigge, et al. 1996 HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression J Immunol 157 2168 2173 8757343
38. K Battle-Miller CA Eby AL Landay, et al. 2002 Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1-infected women J Infect Dis 185 439 447 10.1086/338828 11865395 (Pubitemid 34142805)
39. P Nag J Kim V Sapiega, et al. 2004 Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads J Infect Dis 190 1970 1978 10.1086/425582 15529262 (Pubitemid 39564703)
40. DN Forthal G Landucci KS Cole, et al. 2006 Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells J Virol 80 9217 9225 10.1128/JVI.02746-05 16940533 (Pubitemid 44359994)
41. VR Gomez-Roman LJ Patterson D Venzon, et al. 2005 Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 J Immunol 174 2185 2189 15699150
42. VR Gomez-Roman RH Florese LJ Patterson, et al. 2006 A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity J Immunol Methods 308 53 67 10.1016/j.jim.2005.09.018 16343526 (Pubitemid 43107954)
43. R Hidajat P Xiao Q Zhou, et al. 2009 Correlation of vaccine-elicited systematic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques J Virol 83 791 801 10.1128/JVI.01672-08 18971271
44. LJ Patterson J Beal T Demberg, et al. 2008 Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A01 negative rhesus macaques Virology 374 322 337 10.1016/j.virol.2007.12.037 18252262
45. DN Forthal PB Gilbert G Landucci T Phan 2007 Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate J Immunol 178 6596 6603 17475891
46. AJ Hessell L Hangartner M Hunter, et al. 2007 Fc receptor but not complement binding is important in antibody protection against HIV Nature 449 101 104 10.1038/nature06106 17805298 (Pubitemid 47373775)
47. JR Mascola 2007 HIV/AIDS: allied responses Nature 449 29 30 10.1038/449029a 17805280 (Pubitemid 47373760)
48. M Huber V von Wyl CG Ammann, et al. 2008 Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked J Virol 82 3834 3842 10.1128/JVI.02569-07 18234794
49. Y Nishiyama S Karle S Planque, et al. 2007 Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit Mol Immunol 44 2707 2718 10.1016/j.molimm.2006.12.005 17222909 (Pubitemid 46240317)
50. OM Durova II Vorobiev IV Smirnov, et al. 2009 Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice Mol Immunol 47 87 95 10.1016/j.molimm.2008.12.020 19201029